MedTrace Logo

Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

NCT05429385 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-06-23

No results posted yet for this study

Summary

A single-center, randomized, double-blind, placebo-controlled, dose escalation, phase I clinical study to evaluate safety and pharmacokinetics of HLX70 in healthy adult volunteers

Conditions

Interventions

DRUG

HLX70

Single-dose, intravenous infusion

DRUG

Placebo

Single-dose, intravenous infusion

Sponsors & Collaborators

  • Hengenix Biotech Inc

    collaborator INDUSTRY

  • Sanyou Biopharmaceuticals(Shanghai)Co., Ltd

    collaborator UNKNOWN

  • Shanghai ZJ Bio-Tech Co., Ltd

    collaborator UNKNOWN

  • Shanghai Henlius Biotech

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-09
Primary Completion
2021-09-06
Completion
2021-09-18
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05429385 on ClinicalTrials.gov